FenoQ Tri-Collagen Peptide (2018.)
Food supplement registered in Latvia
Register snapshot dated 2 May 2025. It does not establish the current status of the product.
- Number published by PVD
- 0000351/2018
- Type
- Food supplement
- Published status
- Status not provided in this export; the validity date is shown separately
- Licence holder
- MB PL Baltija
- Manufacturer
- Ražots Zviedrijā pēc MB
- Origin
- Lietuva
- Register snapshot
- 2 May 2025
- Recommended daily intake (Latvian text)
- 1 pudelīte dienā
- Published pack size
- pudelītes pa 25ml
- Published packaging
- 350ml (14x25ml)
This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.
The foreign register category does not determine the regulatory category of the product in France.
Published composition
| Published name | Published text and quantity | Recognised ingredient | Role or context |
|---|---|---|---|
| C VITAMĪNS | vitamins ; C VITAMĪNS ; 120 ; mg | Vitamine C | Vitamin or mineral |
| B6 VITAMĪNS | vitamins ; B6 VITAMĪNS ; 1 ; mg | Vitamine B6 | Vitamin or mineral |
| PANTOTĒNSKĀBE | vitamins ; PANTOTĒNSKĀBE ; 2 ; mg | Acide pantothénique (vitamine B5) | Vitamin or mineral |
| BIOTĪNS | vitamins ; BIOTĪNS ; 200 ; μg | Biotine (vitamine B8) | Vitamin or mineral |
| B12 VITAMĪNS | vitamins ; B12 VITAMĪNS ; 5 ; μg | Vitamine B12 | Vitamin or mineral |
| Varš | minerals ; Varš ; 1000 ; μg | Cuivre | Vitamin or mineral |
| Žeņšeņa sakņu pulveris | plants ; Žeņšeņa sakņu pulveris ; Panax ginseng ; 30 ; mg | panax ginseng | Plant |
| Sējas lucernas lakstu pulveris | plants ; Sējas lucernas lakstu pulveris ; Medicago sativa ; 250 ; μg | medicago sativa | Plant |
| Brokoļu pulveris | plants ; Brokoļu pulveris ; Brassica oleracea var. italica ; 250 ; μg | brassica oleracea | Plant |
| Spirulīnas pulveris | plants ; Spirulīnas pulveris ; Spirulina platensis ; 250 ; μg | spirulina platensis | Plant |
| Vīnogu sēklu pulveris | plants ; Vīnogu sēklu pulveris ; Vitis vinifera ; 250 ; μg | vitis vinifera | Plant |
| Citronlapu morindas augļu pulveris | plants ; Citronlapu morindas augļu pulveris ; Morinda citrifolia ; 250 ; μg | morinda citrifolia | Plant |
| Dižbrūklenes augļu pulveris | plants ; Dižbrūklenes augļu pulveris ; Vaccinium macrocarpon ; 250 ; μg | vaccinium macrocarpon | Plant |
| Godži ogu pulveris | plants ; Godži ogu pulveris ; Lycium barbarum ; 250 ; μg | lycium barbarum | Plant |
| Meža aveņu ogu pulveris | plants ; Meža aveņu ogu pulveris ; Rubus idaeus ; 250 ; μg | rubus idaeus | Plant |
| Acerolas augļu pulveris | plants ; Acerolas augļu pulveris ; Malpighia emarginata ; 250 ; μg | malpighia emarginata | Plant |
| Parasto melleņu augļu pulveris | plants ; Parasto melleņu augļu pulveris ; Vaccinium myrtillus ; 250 ; μg | vaccinium myrtillus | Plant |
| Acai palmu augļu pulveris | plants ; Acai palmu augļu pulveris ; Euterpe oleracea ; 250 ; μg | euterpe oleracea | Plant |
| Parastā granātābola augļu pulveris | plants ; Parastā granātābola augļu pulveris ; Punica granatum ; 250 ; μg | punica granatum | Plant |
| Mandarīnu augļu mizas pulveris | plants ; Mandarīnu augļu mizas pulveris ; Citrus reticulata ; 250 ; μg | citrus reticulata | Plant |
| Divdaivu ginka lapu pulveris | plants ; Divdaivu ginka lapu pulveris ; Ginkgo biloba ; 250 ; μg | ginkgo biloba | Plant |
| Īstās alvejas stublāju un lapu pulveris | plants ; Īstās alvejas stublāju un lapu pulveris ; Aloe barbadensis ; 250 ; μg | Not recognised | Role not identified |
| Tējas krūma (Zaļās tējas) lapu pulveris | plants ; Tējas krūma (Zaļās tējas) lapu pulveris ; Camellia sinensis ; 250 ; μg | camellia sinensis | Plant |
| Hialuronskābe | otherIngredients ; Hialuronskābe ; 6,25 ; mg | Not recognised | Role not identified |
| Kolagēns | otherIngredients ; Kolagēns ; 10000 ; mg | Not recognised | Role not identified |
| Silīcija dioksīds | otherIngredients ; Silīcija dioksīds ; 7 ; mg | Listed as food additive E 551 (EU Union list) | Role not identified |
| Lecitīns | otherIngredients ; Lecitīns ; 250 ; μg | Not recognised | Role not identified |
| Likopēns | otherIngredients ; Likopēns ; 250 ; μg | Listed as food additive E 160d (EU Union list) | Role not identified |
| Koenzīms Q10 | otherIngredients ; Koenzīms Q10 ; 250 ; μg | Not recognised | Role not identified |
| Attīrīts ūdens | otherIngredients ; Attīrīts ūdens | Not recognised | Role not identified |
| Fruktoze | otherIngredients ; Fruktoze | Not recognised | Role not identified |
| Ogu garšas aromatizētājs | otherIngredients ; Ogu garšas aromatizētājs | Not recognised | Role not identified |
| Ksantāna sveķi (E 415) | otherIngredients ; Ksantāna sveķi (E 415) | Listed as food additive E 415 (EU Union list) | Role not identified |
| Baltā jamsa (Dioscorea alata) augļu ekstrakts | otherIngredients ; Baltā jamsa (Dioscorea alata) augļu ekstrakts | dioscorea alata | Plant |
| Kālija sorbāts (E 202) | otherIngredients ; Kālija sorbāts (E 202) | Listed as food additive E 202 (EU Union list) | Role not identified |
| Nātrija benzoāts (E 211) | otherIngredients ; Nātrija benzoāts (E 211) | Listed as food additive E 211 (EU Union list) | Role not identified |
| Citronskābe (E 330) | otherIngredients ; Citronskābe (E 330) | Listed as food additive E 330 (EU Union list) | Role not identified |
| Steviolglikozīdi (E 960) | otherIngredients ; Steviolglikozīdi (E 960) | Not recognised | Role not identified |
Quantities are reproduced as published. The export does not specify their basis: the recommended daily intake cannot be used to calculate a daily dose. No daily dose is estimated. Latvian names are retained without translation.
Manufacturer countries
Lietuva
French and European references for recognised ingredients
- Conditions légales
Brassica oleracea L.: L'étiquetage doit comporter un avertissement recommandant aux personnes ayant une hypothyroïdie ou un traitement de la thyroïde de consulter leur médecin.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Camellia sinensis (L.) Kuntze: Seules sont admises la poudre issue du broyage des feuilles et les préparations obtenues à partir des solvants suivants : l'eau, l'alcool à 25 % (v/v), ainsi que les solvants autorisés pour la décaféination ou la suppression des matières irritantes et amères. Les recommandations d'emploi ne doivent pas conduire à une ingestion quotidienne d'EGCG supérieure à 300 mg. L'étiquetage doit comporter des avertissements déconseillant leur prise en dehors des repas, ainsi que leur consommation par les enfants, les adolescents, les femmes enceintes ou allaitantes.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Ginkgo biloba L.: L'étiquetage des compléments alimentaires qui contiennent la feuille de la plante Ginkgo biloba L. doit comporter un avertissement avec la teneur suivante: "Consultez votre médecin en cas de prise simultanée d'anticoagulants."
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Medicago sativa L.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Contains tea (Camellia sinensis). Green tea extracts must provide less than 800 mg of epigallocatechin-3-gallate per daily portion, with mandatory warnings.
annexe III, partie B (règlement (UE) 2022/2340). Regulation (EC) No 1925/2006, latest consolidated version, retrieved 21 October 2026, source updated 26 November 2025.
- Information
Amount read: 250 µg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
spirulina platensis is on the list of plants allowed in food supplements (Order of 24 June 2014).
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
vitis vinifera is on the list of plants allowed in food supplements (Order of 24 June 2014).
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
morinda citrifolia is on the list of plants allowed in food supplements (Order of 24 June 2014).
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
vaccinium macrocarpon is on the list of plants allowed in food supplements (Order of 24 June 2014).
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
lycium barbarum is on the list of plants allowed in food supplements (Order of 24 June 2014).
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
rubus idaeus is on the list of plants allowed in food supplements (Order of 24 June 2014).
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
malpighia emarginata is not on the plant list of the Order of 24 June 2014: this is not a prohibition (a product legally sold in another Union country may contain it).
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
vaccinium myrtillus is on the list of plants allowed in food supplements (Order of 24 June 2014).
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
euterpe oleracea is on the list of plants allowed in food supplements (Order of 24 June 2014).
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
punica granatum is on the list of plants allowed in food supplements (Order of 24 June 2014).
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
Amount read: 120 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
French reference: maximum dose of 180 mg a day (Order of 9 May 2006, not revised since November 2006).
French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Information
citrus reticulata is on the list of plants allowed in food supplements (Order of 24 June 2014).
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
ginkgo biloba is on the list of plants allowed in food supplements (Order of 24 June 2014). Restriction: L'étiquetage des compléments alimentaires qui contiennent la feuille de la plante Ginkgo biloba L. doit comporter un avertissement avec la teneur suivante: "Consultez votre médecin en cas de prise simultanée d'anticoagulants."
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
camellia sinensis is on the list of plants allowed in food supplements (Order of 24 June 2014). Restriction: Seules sont admises la poudre issue du broyage des feuilles et les préparations obtenues à partir des solvants suivants : l'eau, l'alcool à 25 % (v/v), ainsi que les solvants autorisés pour la décaféination ou la suppression des matières irritantes et amères. Les recommandations d'emploi ne doivent pas conduire à une ingestion quotidienne d'EGCG supérieure à 300 mg. L'étiquetage doit comporter des avertissements déconseillant leur prise en dehors des repas, ainsi que leur consommation par les enfants, les adolescents, les femmes enceintes ou allaitantes.
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
Contains tea (Camellia sinensis). Green tea extracts must provide less than 800 mg of epigallocatechin-3-gallate per daily portion, with mandatory warnings.
annexe III, partie B (règlement (UE) 2022/2340). Regulation (EC) No 1925/2006, latest consolidated version, retrieved 21 October 2026, source updated 26 November 2025.
- Information
Amount read: 6,25 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
Amount read: 10 000 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
Amount read: 7 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
Amount read: 1 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
French reference: maximum dose of 2 mg a day (Order of 9 May 2006, not revised since November 2006).
French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Information
EFSAEuropean Food Safety Authority. reference for adults: 12 mg a day, food included (safety limit).
EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), retrieved 21 October 2026.
- Information
dioscorea alata is not on the plant list of the Order of 24 June 2014: this is not a prohibition (a product legally sold in another Union country may contain it).
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
Amount read: 2 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
Amount read: 200 µg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
Amount read: 5 µg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
Amount read: 1 000 µg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
French reference: maximum dose of 2,000 µg a day (Order of 9 May 2006, not revised since November 2006).
French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Information
EFSA reference for adults: 5 mg a day, food included (safety limit).
EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), retrieved 21 October 2026.
- Information
Amount read: 30 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
panax ginseng is on the list of plants allowed in food supplements (Order of 24 June 2014).
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
medicago sativa is on the list of plants allowed in food supplements (Order of 24 June 2014). Restriction: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
brassica oleracea is on the list of plants allowed in food supplements (Order of 24 June 2014). Restriction: L'étiquetage doit comporter un avertissement recommandant aux personnes ayant une hypothyroïdie ou un traitement de la thyroïde de consulter leur médecin.
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
Unrecognised ingredients are not assessed. The absence of a signal does not establish product compliance.
Official source
Internet Archive copy dated 3 May 2025
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Žeņšeņa sakņu pulveris
Read the warning, when it applies and the studies cited
PANAX GINSENG
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Vuksan et al. 2008; Seely et al. 2008; Sievenpiper et al. 2006; ESCOP 2003; Tetsutani et al. 2000; Sotaniemi et al. 1995; Chin 1991).
Sources cited by Health Canada (8)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Chin RKH. Ginseng and common pregnancy disorders. Asia-Oceania Journal of Obstetrics and Gynaecology 1991;17(4):379-380. PubMed
- ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- Seely D, Dugoua JJ, Perri D, Mills E, Koren G. Safety and efficacy of Panax ginseng during pregnancy and lactation. The Canadian Journal of Clinical Pharmacology 2008;15(1):e87-e94.
- Sievenpiper JL, Sung MK, Buono MD, Seung-Lee K, Nam KY, Arnason JT, Leiter LA, Vuksan V. Korean red ginseng rootlets decrease acute postprandial glycemia: results from sequential preparation- and dose-finding studies. Journal of the American College of Nutrition 2006;25(2):100-107. PubMed Randomised trial
- Sotaniemi EA, Haapakoski E, Rautio A. Ginseng therapy in non-insulin-dependent diabetic patients. Diabetes Care 1995;18(10):1373-1375. PubMed Clinical trial
- Tetsutani T, Yamamura M, Yamaguchi T, Onoyama O, Kono M. Can red ginseng control blood glucose in diabetic patients. The Ginseng Review 2000;28:44-47.
- Vuksan V, Sung MK, Sievenpiper JL, Stavro PM, Jenkins AL, Buono MD, Lee KS, Leiter LA, Nam KY, Arnason JT, Choi M, Naeem A. Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety. Nutrition, Metabolism & Cardiovascular Diseases 2008;18(1):46-56. PubMed Randomised trial
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking antidepressant medication, blood thinners or digoxin (Brinker 2010; Lee et al. 2008a; Dasgupta and Reyes 2005; Janetzki and Morreale 1997; Gonzalez-Seijo et al. 1995; Shader and Greenblatt 1988; Jones and Runikis 1987; Shader and Greenblatt 1985).
Sources cited by Health Canada (8)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Dasgupta A, Reyes MA. Effect of Brazillian, Indian, Siberian, Asian, and North American ginseng on serum digoxin measurement by immunoassays and binding of digoxin-like immunoreactive components of ginseng with Fab Fragment of antidigoxin antibody (Digiband). American Journal of Clinical Pathology 2005;124(2):229-236. PubMed
- Gonzalez-Seijo JC, Ramos YM, Lastra I. Manic episode and ginseng: report of a possible case. Journal of Clinical Psychopharmacology 1995;15(6):447-448. PubMed Case report
- Janetzki K, Morreale AP. Probable interaction between warfarin and ginseng. American Journal of Health-System Pharmacy 1997;54(6):692-693.
- Jones BD, Runikis AM. Interaction of ginseng with phenelzine. Journal of Clinical Pharmacology 1987;7(3):201-202. PubMed Case report
- Lee SH, Ahn YM, Ahn SY, Doo HK, Lee BC. Interaction between warfarin and Panax ginseng in ischemic stroke patients. The Journal of Alternative and Complementary Medicine 2008a;14(6):715-721. PubMed Randomised trial
- Shader RI, Greenblatt DJ. Bees, ginseng and MAOIs revisited. Journal of Clinical Psychopharmacology 1988;8(4):235. PubMed Case report
- Shader RI, Greenblatt DJ. Phenelzine and the dream machine – ramblings and reflections. Journal of Clinical Psychopharmacology 1985;5(2):65. PubMed Case report
Contraindications
Condition of application: Traditional Chinese Medicine.
Do not use in cases of yin deficiency with heat signs, heat excess, or in the absence of significant qi deficiency (Bensky et al. 2004).
Sources cited by Health Canada (1)
- Bensky D, Clavey, Stöger E, Gamble A. Chinese Herbal Medicine: Materia Medica. 3rd edition. Seattle (WA): Eastland Press, Incorporated; 2004.
Known adverse reactions
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience insomnia, anxiety or headaches (Lee et al. 2008b; Vuksan et al 2008; de Andrade et al.2007; Sievenpiper et al. 2006; Coon and Ernst 2002; Ellis and Reddy 2002; Scaglione et al. 2001; Siegel 1979).
Sources cited by Health Canada (8)
- Coon JT, Ernst E. Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Safety 2002;25(5):323-344. PubMed Systematic review
- de Andrade E, de Masquita AA, de Almeida Claro J, de Andrade PM, Ortiz V, Paranhos M, Srougi M. Study of the efficacy of Korean Red Ginseng in the treatment of erectile dysfunction. Asian Journal of Andrology 2007;9(2):241-244.
- Ellis JM, Reddy P. Effects of Panax ginseng on quality of life. The Annals of Pharmacotherapy 2002;36(3):375-379. PubMed Randomised trial
- Lee ST, Chu K, Sim JY, Heo JH, Kim M. Panax ginseng enhances cognitive performance in Alzheimer disease. Alzheimer Disease and Associated Disorders 2008b;22(3):222-226. PubMed Randomised trial
- Scaglione F, Weiser K, Alessandria M. Effects of the standardised ginseng extract G115 in patients with chronic bronchitis. Clinical Drug Investigation 2001;21(1):41-45.
- Siegel RK. Ginseng abuse syndrome. Problems with the panacea. The Journal of the American Medical Association 1979;241(15):1614-1615. PubMed
- Sievenpiper JL, Sung MK, Buono MD, Seung-Lee K, Nam KY, Arnason JT, Leiter LA, Vuksan V. Korean red ginseng rootlets decrease acute postprandial glycemia: results from sequential preparation- and dose-finding studies. Journal of the American College of Nutrition 2006;25(2):100-107. PubMed Randomised trial
- Vuksan V, Sung MK, Sievenpiper JL, Stavro PM, Jenkins AL, Buono MD, Lee KS, Leiter LA, Nam KY, Arnason JT, Choi M, Naeem A. Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety. Nutrition, Metabolism & Cardiovascular Diseases 2008;18(1):46-56. PubMed Randomised trial
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
- Sējas lucernas lakstu pulveris
Read the warning, when it applies and the studies cited
ALFALFA - MEDICAGO SATIVA
Route of administration: Oral
Cautions and warnings
Applies to products providing more than 900 mg of Alfalfa dried herb top/leaf, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners, birth control medication or hormone therapy (Brinker 2010; Barnes et al. 2007; Boon and Smith 2004).
Sources cited by Health Canada (3)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): Pharmaceutical Press; 2007.
- Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
- Brinker F. Herb Contraindications and Drug Interactions, 4e édition. Sandy (OR): Eclectic Medical Publications; 2010.
Contraindications
Condition of application: All products.
Do not use if you are pregnant or breastfeeding (Brinker 2010; Barnes et al. 2007; Boon and Smith 2004).
Sources cited by Health Canada (3)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): Pharmaceutical Press; 2007.
- Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
- Brinker F. Herb Contraindications and Drug Interactions, 4e édition. Sandy (OR): Eclectic Medical Publications; 2010.
Applies to products providing more than 900 mg of Alfalfa dried herb top/leaf, per day.
Do not use if you have a history of systemic lupus erythematosus (Brinker 2010; Barnes et al. 2007; Boon and Smith 2004).
Sources cited by Health Canada (3)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): Pharmaceutical Press; 2007.
- Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
- Brinker F. Herb Contraindications and Drug Interactions, 4e édition. Sandy (OR): Eclectic Medical Publications; 2010.
- Spirulīnas pulveris
Read the warning, when it applies and the studies cited
Spirulina
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Condition of application: Allergic rhinitis.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
- Dižbrūklenes augļu pulveris
Read the warning, when it applies and the studies cited
CRANBERRY - VACCINIUM MACROCARPON
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).
Sources cited by Health Canada (2)
- Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Randomised trial
- Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).
Sources cited by Health Canada (4)
- Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Case report
- Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.
Condition of application: (Recurrent) urinary tract infection.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 27 March 2026
DRIED CRANBERRY JUICE
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).
Sources cited by Health Canada (2)
- Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Randomised trial
- Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).
Sources cited by Health Canada (4)
- Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Case report
- Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.
Condition of application: (Recurrent) urinary tract infection.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
- Parasto melleņu augļu pulveris
Read the warning, when it applies and the studies cited
BILBERRY - VACCINIUM MYRTILLUS - Buccal
Route of administration: Buccal (Blumenthal et al. 2000)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 30 January 2026
BILBERRY - VACCINIUM MYRTILLUS - Oral
Route of administration: Oral (Blumenthal et al. 2000)
Cautions and warnings
Condition of application: Relief of diarrhea.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: Slowing the progression of disorders of the eye and to relieve symptoms related to non-complicated CVI.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.
- Acai palmu augļu pulveris
Read the warning, when it applies and the studies cited
ACAI – EUTERPE OLERACEA
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (derMarderosian and Beutler 2008).
Sources cited by Health Canada (1)
- derMarderosian A, Beutler JA, editors. The Review of Natural Products. [Acai: Date of issue January 2008]. St Louis (MO): Facts and Comparisons, Wolters Kluwer Health; Printed in 2008 and Updated to April 2012.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (derMarderosian and Beutler 2008).
Sources cited by Health Canada (1)
- derMarderosian A, Beutler JA, editors. The Review of Natural Products. [Acai: Date of issue January 2008]. St Louis (MO): Facts and Comparisons, Wolters Kluwer Health; Printed in 2008 and Updated to April 2012.
- Parastā granātābola augļu pulveris
Read the warning, when it applies and the studies cited
- Divdaivu ginka lapu pulveris
Read the warning, when it applies and the studies cited
GINKGO - GINKGO BILOBA
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Blumenthal et al. 2000; WHO 1999).
Sources cited by Health Canada (3)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Newton (MA): Integrative Medicine Communications; 2000.
- WHO 1999: World Health Organization. WHO monographs on selected medicinal plants, Volume 1. Geneva (CHE): World Health Organization; 1999.
- OMS 1999 : Organisation mondiale de la santé (OMS). Monographs on selected medicinal plants, Volume 1. Genève (CHE): Organisation mondiale de la santé; 1999.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking diabetes, high blood pressure or seizure medications (Brinker 2010).
Sources cited by Health Canada (1)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
Contraindications
Do not use if you are having a surgery (Gardner and McGuffin 2013).
Sources cited by Health Canada (1)
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.
Do not use if you are taking blood thinners or other health products that affect blood coagulation (Gardner and McGuffin 2013; Brinker 2010; Bent 2005).
Sources cited by Health Canada (3)
- Bent S, Goldberg H, Padula A, Avins AL. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature. Journal of General Internal Medicine 2005;20(7):657-661. PubMed Systematic review
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “FenoQ Tri-Collagen Peptide (2018.)”, https://compoatlas.com/en/supplements/latvia/7295-fenoq-tri-collagen-peptide-2018, updated 28 October 2026.